Keyword Search
Free Preview
Login    Register   

Login to your account

No Account Yet? Fields marked with an asterisk (*) are required.

Please enter a valid Username. No spaces, at least 2 characters and must contain only letters and numbers.
Please enter a valid Password. No spaces, at least 4 characters and must contain only letters and numbers.
Passwords do not match.
Please enter a valid e-mail address.
E-mails do not match. ?>


Call for Articles


By purchasing an article in PDF format, you are agreeing to follow our Article Policy.

Use the "Buy Now" button to purchase an article.  Once checkout is complete, a download link will be sent to the email address that you provide during checkout.


Use the KEYWORD search located in the top left column to look for keywords, authors, and titles. If you still can't find what you're looking for, please This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Manufacturing and Testing of a Multi-Clade Adenoviral Vector-Based Candidate Vaccine Against Human Immunodeficiency Virus

by Bryan T. Butman, PhD, Jason Gall, PhD, Douglas E. Brough, PhD, J. Michael Sowers; Perry Newton, Victoria Kulesa Haque, Alena Lizonova, PhD, Phil Gomez, PhD, and Rebecca Sheets, PhD
Volume 5, Issue 2 (Summer 2006)

Despite 20 years of in tens ive research, the development of an effective vaccine to combat the worldwide AIDS pandemic remains an elusive goal. Currently, more than 40 million individuals are infected with human immunodeficiency virus (HIV) and there have been more than 25 million related deaths. Globally, the rate of new infections is alarming, with ten new infections occurring every minute. Ninety-five percent of these infections occur in the developing world. Several significant challenges face the development of an effective HIV vaccine...

Citation:
Butman BT, Gall J, Brough DE, Sowers JM, Newton P, Kulesa Haque V, Lizonova A, Gomez P, Sheets R. Manufacturing and Testing of a Multi-Clade Adenoviral Vector-Based Candidate Vaccine Against Human Immunodeficiency Virus.
BioProcess J, 2006; 5(2): 15-19. https://doi.org/10.12665/J52.Butman.

 
Polysorbate-80 Determination in BG00002 MAb Using Cobalt Complexation

by David Malliaros, PhD, Drago Clifton, and Paivi Kauppinen
Volume 5, Issue 2 (Summer 2006)

Polysorbate-80, or polysorbitan mono-oleate, a nonionic surfactant commercially referred to as Tween-80, is commonly employed as an excipient in the biopharmaceutical industry due to its low toxicity as well as its ability to solubilize hydrophobic molecules. Thus, polysorbate-80 is employed as a stabilizer in order to control the formation of protein aggregates and larger particulates in biopharmaceutical drug substance and drug product formulations. Guidelines published by The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and the United States Pharmacopeia (USP) classify excipients such as polysorbate-80 as major components in biopharmaceutical formulations and specify that these types of compounds be quantified using a validated analytical method...

Citation:
Malliaros D, Clifton D, Kauppinen P. Polysorbate-80 Determination in BG00002 MAb Using Cobalt Complexation.
BioProcess J, 2006; 5(2): 37-43. https://doi.org/10.12665/J52.Malliaros.

 
A New Class of Therapeutic Vaccines Produced in Insect Cells for the Treatment of Chronic Viral Infections

by Rajan George, PhD, Bruce Motyka, PhD, Allan Ma, PhD, Dakun Wang, PhD, Hubert Eng, PhD, Biwen Xu, PhD, Robert Polakowski, PhD, Adam Szpacenko, PhD, Antoine A. Noujaim, PhD, ScD, and D. Lorne J. Tyrrell, MD, PhD
Volume 5, Issue 2 (Summer 2006)

Chronic viral infections are major healthcare issues. Hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), and human immunodeficiency virus (HIV) are prime examples of viruses which cause chronic infections. HBV is a member of a family of DNA viruses that primarily infect liver cells which can lead to acute or chronic liver disease. Approximately 3–5% of adults and 90% of infants infected by HBV become chronic carriers of the virus. More than 350 million people worldwide are chronically infected by HBV. Chronic HBV carriers have a significant probability of developing cirrhosis of the liver and hepatocellular carcinoma. There are effective prophylactic vaccines for HBV infection, but these have proven ineffective against chronic infections. Antiviral agents are effective in controlling the viremia, but the emergence of mutant strains of the virus is a cause for concern...

Citation:
George R, Motyka B, Ma A, Wang D, Eng H, Xu B, Polakowski R, Szpacenko A, Noujaim AA, Tyrrell DLJ. A New Class of Therapeutic Vaccines Produced in Insect Cells for the Treatment of Chronic Viral Infections.
BioProcess J, 2006; 5(2): 27-33. https://doi.org/10.12665/J52.George.

 
Regulatory Overview of Conducting Gene Therapy Clinical Trials in the United States

by William Lee, PhD
Volume 5, Issue 2 (Summer 2006)

Since the first gene therapy trials were conducted 25 years ago, there have been high expectations from the public, and much attention from investors, that previously incurable diseases would be cured by gene therapy. Still, despite numerous gene therapy clinical trials for many different indications, there are no approved gene therapy drugs in the United States. In 1999, one gene therapy patient died during clinical trials, the first ever. This highly publicized event led to heightened regulatory scrutiny over all such trials. Then in 2003 and 2005, three subjects developed leukemia as a direct consequence of gene therapy; one of them eventually passed away. The regulatory response stemming from these incidents led to greater regulatory oversight in gene therapy, as compared to other investigational drugs and biologics...

Citation:
Lee W. Regulatory Overview of Conducting Gene Therapy Clinical Trials in the United States.
BioProcess J, 2006; 5(2): 45-50. https://doi.org/10.12665/J52.Lee.

 
Smart-Flow Technology: Optimizing Tangential Flow Filtration

by Henry B. (Hank) Kopf and Marcelo Tellez
Volume 5, Issue 2 (Summer 2006)

Optimal process development creates unit operations that effectively generate, separate, and concentrate a broad array of products. Historically, tangential flow filtration (TFF) process capabilities have been limited by technological and flow restrictions. Recent innovations in TFF module design have dramatically increased the capabilities of TFF to better achieve processing objectives. NCSRT has established a best practices protocol for developing clarification, fractionation, and concentration processes for mammalian, bacteria, yeast, insect, and virus based production systems. This article presents the development platform, supplemented with application-specific expertise...

Citation:
Kopf HB, Tellez M. Smart-Flow Technology: Optimizing Tangential Flow Filtration.
BioProcess J, 2006; 5(2): 51-58. https://doi.org/10.12665/J52.Kopf.

 
Rapid Production of Recombinant Proteins Utilizing the PERLXpress Platform

by Richard W. Welch, PhD, Jim Campbell, Al Toledo, Dave Davis, Helen Latzgo, Gary Haupt, Kim Love, Jae M. Sly, Gary Cohen, Roselyn Eisenberg, J. Charles Whitbeck, Lydia Aldaz-Carroll, Huan Lou, David E. Lenz, Pinal C. Patel, and Douglas M. Cerasoli
Volume 5, Issue 2 (Summer 2006)

The developing biotechnology community may offer solutions and hope for recent world events that have focused attention on the vulnerability of the world’s population. Concerns about new pandemics have been raised by the emergence of new influenza strains and the re-emergence of older and even more highly virulent strains. In addition, there are fears that bioterrorism could involve agents such as anthrax or smallpox, and these threats become even more of a concern when you consider the increased mobility of such organisms via today’s commercial aviation. The ability of the biomedical community to respond rapidly to these shifting threats is more important than ever...

Citation:
Welch RW et al. Rapid Production of Recombinant Proteins Utilizing the PERLXpress Platform.
BioProcess J, 2006; 5(2): 63-70. https://doi.org/10.12665/J52.Welch.

 
<< Start < Prev 41 42 43 44 45 46 47 48 49 50 Next > End >>

Endorsed Events
Please update your Flash Player to view content.
Please update your Flash Player to view content.
Please update your Flash Player to view content.
Journal on iPad